


AMENDMENTS TO THE CLAIMS

1-4 (Canceled)

5. (Currently Amended) A monoclonal catalytic antibody specific for a transition state analog of ~~claim 1~~ having the formula:



wherein R₁ is a hydrogen atom, an amino protecting group, or a carrier molecule;

and the salts and esters thereof;

wherein said antibody ~~that~~ catalyzes the deamidation of asparagine to aspartic acid.

6. (Currently Amended) The monoclonal antibody of claim 5 that was raised against the transition state analog of ~~claim 1~~ wherein R₁ is an immunoconjugate carrier molecule.

7. (Original) The monoclonal antibody of claim 5 wherein the antibody is murine.

8. (Original) The monoclonal antibody of claim 5 wherein the antibody is human.

9. (Original) The monoclonal antibody of claim 5, wherein the antibody is a human one of the IgG class.

10. (Original) The monoclonal antibody of claim 5, wherein the antibody is a human one of the IgG₂ class.

Appl. No. : 10/821,626
Filed : April 9, 2004

11. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable amount of the monoclonal antibody of claim 5 and one or more pharmaceutically acceptable carriers therefor.

12. (Original) The pharmaceutical composition of claim 11, wherein the monoclonal antibody is murine.

13. (Original) The pharmaceutical composition of claim 11, wherein the monoclonal antibody is human.

14. (Original) The pharmaceutical composition of claim 11, wherein the monoclonal antibody is a human one of the IgG class.

15. (Original) The pharmaceutical composition of claim 11, wherein the monoclonal antibody is a human one of the IgG₂ class.

16-58 (Canceled)

59. (Previously Presented) The monoclonal antibody of Claim 6, wherein the immunoconjugate carrier molecule comprises keyhole limpet hemocyanin (KLH).